Who is winning? Who is losing? From the underserved to millennial blood to pivots to video, we dig in.
Impact Biomedicines' exit this week for a whopping $7B is the largest since AbbVie's $10B+ acquisition of Stemcentrx in 2016. In all, 14 cancer therapy companies have exited for over $1B since 2014.
Celgene and Boehringer Ingelheim Venture Fund are two standout corporate investors ramping up their cancer therapeutics portfolios.
The retail giant's latest patent details a system for shoppers to see 3D renderings of their fresh items online prior to purchasing them for delivery or pick-up.
Who is winning? Who is losing? From drugs discarded by big pharma to Waze to Intel and future Nvidias, we dig in.
Startups developing improved sensor technologies are hot investment and acquisition targets as they compete to supply growing markets in autonomous driving, drones, and beyond.